Carlos Santos, MD
Pulmonary Disease · North Miami Beach, FLNPI 1851343578
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $252,443 of the $312,182 with a category attached, or 80.9%. 53 manufacturers reported payments, led by GSK at 38.5% of the total. Reporting peaked in 2023 at $77,909 and has fallen 66.7% since, to $25,946 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,765 payments — averaging $176.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$120K
- Mallinckrodt Hospital Products Inc.$106K
- Mallinckrodt Enterprises LLC$25K
- Actelion Pharmaceuticals US, Inc.$12K
- Mylan Specialty L.p.$8K
- AstraZeneca$6K
- plus $34K from 47 others
Across 44 payments — averaging $6984.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$307K
What the payments were for
- Consulting fees$2,9301%
- Speaking & faculty fees$252,44381%
- Travel & lodging$6,9602%
- Food & beverage$48,75516%
- Education$1,0430%
- Gifts$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$129,214
- TRELEGY ELLIPTA$56,938
- AREXVY$41,874
- Yupelri$10,134
- UPTRAVI$3,267
- Inspire Upper Airway Stimulation System$2,944
- OPSUMIT$2,844
- PURIFIED CORTROPHIN GEL$2,555
- BREZTRI$1,089
- NUCALA$813
- FISHER & PAYKEL HEALTHCARE$673
- Inspire$638
- DUPIXENT$601
- Wakix$410
- Adempas$375
- LINZESS$375
- TEZSPIRE$372
- TYVASO$369
- XOLAIR$272
- FASENRA$250
How this compares
$312,182 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 14 | $1,000,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,135 | $828,275 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 517 | $352,297 |
| UptraviSelexipag | 13 | $302,608 |
| NucalaMepolizumab | 71 | $263,593 |
| OpsumitMacitentan | 18 | $225,515 |
| Dupixent PenDupilumab | 55 | $220,422 |
| TezspireTezepelumab-Ekko | 43 | $181,815 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $179,685 |
| XolairOmalizumab | 38 | $155,813 |
| Breo ElliptaFluticasone/Vilanterol | 335 | $154,095 |
| OfevNintedanib Esylate | 12 | $146,878 |
| SymbicortBudesonide/Formoterol Fumarate | 401 | $106,238 |
| EliquisApixaban | 153 | $76,368 |
| Ambrisentan | 32 | $71,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $120,323 | $1,312,6351,710 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $106,361 | $1,000,61814 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $6,332 | $640,350961 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $12,109 | $528,12331 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,912 | $257,051211 claims |
| Insmed, Inc.Arikayce | $1,985 | $179,68512 claims |
| PfizerEliquis | $87 | $76,368153 claims |
| AbbVieCreon, Linzess | $851 | $59,27242 claims |
| Lilly USA, LLCMounjaro, Trulicity | $21 | $29,07528 claims |
| NovartisEntresto | $193 | $15,76722 claims |
| MerckBelsomra | $364 | $9,04020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in North Miami Beach
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.